Results 221 to 230 of about 495,743 (373)

Gamma-spectrometric measurement of radioactivity in agricultural soils of the Lombardia region, northern Italy.

open access: yesJournal of Environmental Radioactivity, 2015
Laura Guidotti   +5 more
semanticscholar   +1 more source

Synthesis and Evaluation of Fluorinated Peptidomimetics Enabling the Development of 18F‐Labeled Radioligands Targeting Muscarinic Acetylcholine Receptor Subtype M3

open access: yesChemMedChem, EarlyView.
Fluorinated peptidomimetics targeting muscarinic acetylcholine receptor subtype M3: Fluorinated peptidomimetic compounds based on a β‐alanine‐glycine scaffold, with lead compound 24 demonstrating high M3 selectivity and submicromolar potency. The first M3‐selective positron emission tomography radioligand, [18F]24, is synthesized and will be evaluated ...
Miguel A. Herrera‐Rueda   +4 more
wiley   +1 more source

GEMS: Underwater spectrometer for long-term radioactivity measurements

open access: yes, 2011
L. Sartini   +9 more
semanticscholar   +1 more source

Impact of Multiple S‐Palmitoylation on Peptide Ionization and Fragmentation in Mass Spectrometry

open access: yesChemistry–Methods, EarlyView.
S‐palmitoylation is selectively introduced at potential modification sites of a model peptide. Modified peptides are then characterized by mass spectrometry, and the sites of modification are unambiguously identified. Lipidation, such as S‐palmitoylation, is an important, reversible post‐translational modification of proteins determining not only their
Elisa Badin, Carla Schmidt
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy